Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Clinical Trials (PDQ®)

Phase III Randomized Study of Lymphadenectomy and Adjuvant External Beam Radiotherapy in Patients With Endometrial Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
First Published: 3/1/1999     Last Modified: 6/20/2011  

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Related Publications
Trial Contact Information
Registry Information

Alternate Title

Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentClosedAny ageOtherMRC-ASTEC
EU-98062, NCT00003749

Objectives

  1. Compare the effects of conventional surgery alone and conventional surgery plus lymphadenectomy in patients with endometrial cancer preoperatively thought to be confined to the uterine corpus.
  2. Determine the effect of postoperative adjuvant external beam radiotherapy on quality of life and survival of a subset of these patients at high risk of relapse and with no macroscopic disease after surgery.

Entry Criteria

Disease Characteristics:

Surgical randomization:

  • Histologically confirmed endometrial carcinoma
  • Disease thought preoperatively to be confined to the uterine corpus

Radiotherapy randomization:

  • Must have disease determined postoperatively to be confined to the uterine corpus, irrespective of pelvic node status
    • No cervical stroma invasion (stage IIB)
  • Must be macroscopically free of disease (no positive para-aortic nodes)
  • Must have high-risk disease defined as one or more of the following:
    • Grade 3 (poorly differentiated)
    • Invasion to the outer half of the myometrium (stage IC)
    • Serous papillary or clear cell type
    • Stage IIA (endocervical glandular involvement)

Prior/Concurrent Therapy:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Patient Characteristics:

Age:

  • Any age

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No other prior or concurrent malignancy likely to interfere with protocol treatment or comparisons
  • Surgical randomization:
    • Must be fit to undergo lymphadenectomy and external beam radiotherapy
  • Radiotherapy randomizations:
    • Must be fit to receive external beam radiotherapy

Expected Enrollment

2300

A minimum of 1400 patients will be accrued for the surgical component of this study and at least 900 patients (including additional patients not participating in the surgical component of this study) will be accrued for the radiotherapy component of this study.

Outline

This is a randomized, multicenter study. Patients are randomized in both the surgery and radiotherapy segments of the study.

  • Surgery: Patients are randomized to 1 of 2 surgery arms.
    • Arm I: Patients undergo conventional surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy).
    • Arm II: Patients undergo conventional surgery as in arm I followed by lymphadenectomy with systematic dissection of the iliac and obturator nodes.
  • Radiotherapy: Patients at high risk of relapse who have no postoperative macroscopic disease are randomized to 1 of 2 radiotherapy arms. (Patients may enter the radiotherapy randomization after surgery off study.)
    • Arm I: Patients receive in 20-25 fractions of external beam radiotherapy (total dose of 40-46 Gy) over 4-5 weeks.
    • Arm II: Patients receive no external beam radiotherapy.

 [Note: Some patients receive vault brachytherapy regardless of radiotherapy randomization.]

Quality of life is assessed before therapy and at 2 and 5 years after therapy.

Patients are followed every 3 months for 1 year and then every 6 months for 1 year.

Published Results

Kitchener HC: The effect of incision in the surgical treatment of endometrial cancer and long-term follow-up of a randomized trial of lymphadenectomy: results of the MRC ASTEC trial. [Abstract] J Clin Oncol 29 (Suppl 15): A-e15583, 2011.

Kitchener H, Swart AM, Qian Q, et al.: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (9658): 125-36, 2009.[PUBMED Abstract]

Barton DP, Naik R, Herod J: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): a randomized study. Int J Gynecol Cancer 19 (8): 1465, 2009.[PUBMED Abstract]

Related Publications

Blake P, Swart AM, Orton J, et al.: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373 (9658): 137-46, 2009.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Medical Research Council Clinical Trials Unit

Claire Amos, Study coordinator
Ph: 44-020-7670-4700 ext. 4795

Registry Information
Official Title A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer
Trial Start Date 1998-04-08
Registered in ClinicalTrials.gov NCT00003749
Date Submitted to PDQ 1999-01-13
Information Last Verified 1999-04-15

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.